Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00129207
- Locations
- 🇺🇸
Medical Center, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00124579
- Locations
- 🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸St. James Healthcare Cancer Care, Butte, Montana, United States
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00118183
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00118144
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00114738
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00111813
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
- Conditions
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00111319
- Locations
- 🇺🇸
Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
- First Posted Date
- 2005-04-13
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00108069
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 37
- Registration Number
- NCT00107341
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00104871
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.